Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Fabry Disease Treatment Market

Fabry Disease Treatment Market Share

Report ID: GMI4237
Published Date: Sep 2022
Report Format: PDF

Download Free Sample

Fabry Disease Treatment Market Share

JCR Pharmaceuticals Co Ltd
Takeda
Amicus Therapeutics
Sanofi
ISU Abaxis

are some of the key players operating in the Fabry disease treatment market. These companies are witnessing product approvals from regulatory players, which will enable them to expand their customer base and presence in the global market. For instance, in August 2021, Amicus Therapeutics announced the European Commission’s approval of its Galafold (migalastat) treatment for adolescent Fabry disease patients. This treatment was designed for patients aged 12 years and older with Fabry disease and an amenable mutation. This move was aimed at enabling the company to strengthen its foothold in the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for Fabry disease treatment registered revenue of over USD 1.7 billion in 2021 and is expected to depict a CAGR of more than 8% through 2030, due to the increasing burden of heart problems in late-onset Fabry disease patients.

The enzyme replacement therapy segment is set to register a revenue of over USD 2.6 billion by 2030, driven by its capability to help identify the underlying disease cause and assist in the breakdown of fatty molecules.

The North America Fabry disease treatment industry size is expected to be valued at more than USD 1 billion by 2030, which can be credited to novel product launches and the growing disease prevalence.

The key companies holding a significant part of the Fabry disease treatment business share include JCR Pharmaceuticals Co Ltd., Takeda, Amicus Therapeutics, Sanofi, and ISU Abaxis, among others.